vs

Side-by-side financial comparison of Intuitive Surgical (ISRG) and Invesco (IVZ). Click either name above to swap in a different company.

Intuitive Surgical is the larger business by last-quarter revenue ($2.8B vs $1.7B, roughly 1.6× Invesco). Intuitive Surgical runs the higher net margin — 29.8% vs -58.9%, a 88.7% gap on every dollar of revenue. On growth, Intuitive Surgical posted the faster year-over-year revenue change (23.0% vs 6.2%). Over the past eight quarters, Intuitive Surgical's revenue compounded faster (17.4% CAGR vs 7.1%).

Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S.

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

ISRG vs IVZ — Head-to-Head

Bigger by revenue
ISRG
ISRG
1.6× larger
ISRG
$2.8B
$1.7B
IVZ
Growing faster (revenue YoY)
ISRG
ISRG
+16.7% gap
ISRG
23.0%
6.2%
IVZ
Higher net margin
ISRG
ISRG
88.7% more per $
ISRG
29.8%
-58.9%
IVZ
Faster 2-yr revenue CAGR
ISRG
ISRG
Annualised
ISRG
17.4%
7.1%
IVZ

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ISRG
ISRG
IVZ
IVZ
Revenue
$2.8B
$1.7B
Net Profit
$826.0M
$-995.9M
Gross Margin
66.1%
Operating Margin
64.8%
-86.2%
Net Margin
29.8%
-58.9%
Revenue YoY
23.0%
6.2%
Net Profit YoY
17.4%
-575.8%
EPS (diluted)
$2.28
$-2.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISRG
ISRG
IVZ
IVZ
Q1 26
$2.8B
Q4 25
$2.9B
$1.7B
Q3 25
$2.5B
$1.6B
Q2 25
$2.4B
$1.5B
Q1 25
$2.3B
$1.5B
Q4 24
$2.4B
$1.6B
Q3 24
$2.0B
$1.5B
Q2 24
$2.0B
$1.5B
Net Profit
ISRG
ISRG
IVZ
IVZ
Q1 26
$826.0M
Q4 25
$794.8M
$-995.9M
Q3 25
$704.4M
$356.4M
Q2 25
$658.4M
$197.4M
Q1 25
$698.4M
$171.1M
Q4 24
$685.7M
$209.3M
Q3 24
$565.1M
$55.0M
Q2 24
$526.9M
$132.2M
Gross Margin
ISRG
ISRG
IVZ
IVZ
Q1 26
66.1%
Q4 25
66.4%
Q3 25
66.4%
Q2 25
66.3%
Q1 25
64.7%
Q4 24
68.0%
Q3 24
67.4%
Q2 24
68.3%
Operating Margin
ISRG
ISRG
IVZ
IVZ
Q1 26
64.8%
Q4 25
30.2%
-86.2%
Q3 25
30.3%
16.5%
Q2 25
30.5%
14.1%
Q1 25
25.7%
18.1%
Q4 24
30.4%
19.6%
Q3 24
28.3%
6.6%
Q2 24
28.2%
13.9%
Net Margin
ISRG
ISRG
IVZ
IVZ
Q1 26
29.8%
Q4 25
27.7%
-58.9%
Q3 25
28.1%
21.7%
Q2 25
27.0%
13.0%
Q1 25
31.0%
11.2%
Q4 24
28.4%
13.1%
Q3 24
27.7%
3.6%
Q2 24
26.2%
8.9%
EPS (diluted)
ISRG
ISRG
IVZ
IVZ
Q1 26
$2.28
Q4 25
$2.19
$-2.61
Q3 25
$1.95
$0.66
Q2 25
$1.81
$-0.03
Q1 25
$1.92
$0.38
Q4 24
$1.89
$0.46
Q3 24
$1.56
$0.12
Q2 24
$1.46
$0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISRG
ISRG
IVZ
IVZ
Cash + ST InvestmentsLiquidity on hand
$1.0B
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$17.6B
$12.2B
Total Assets
$20.1B
$27.1B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
$5.9B
$1.0B
Q3 25
$4.9B
$973.1M
Q2 25
$5.3B
$922.7M
Q1 25
$4.5B
$821.7M
Q4 24
$4.0B
$986.5M
Q3 24
$4.2B
$1.0B
Q2 24
$4.8B
$878.5M
Total Debt
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
$1.8B
Q3 25
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
Q3 24
$890.3M
Q2 24
$890.1M
Stockholders' Equity
ISRG
ISRG
IVZ
IVZ
Q1 26
$17.6B
Q4 25
$17.8B
$12.2B
Q3 25
$16.9B
$14.0B
Q2 25
$17.8B
$13.9B
Q1 25
$17.1B
$14.7B
Q4 24
$16.4B
$14.6B
Q3 24
$15.6B
$14.8B
Q2 24
$14.7B
$14.6B
Total Assets
ISRG
ISRG
IVZ
IVZ
Q1 26
$20.1B
Q4 25
$20.5B
$27.1B
Q3 25
$19.4B
$28.4B
Q2 25
$20.2B
$28.5B
Q1 25
$19.2B
$28.1B
Q4 24
$18.7B
$27.0B
Q3 24
$17.7B
$27.5B
Q2 24
$16.6B
$27.2B
Debt / Equity
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
0.15×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.06×
Q2 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISRG
ISRG
IVZ
IVZ
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
$892.5M
$455.8M
Q3 25
$841.0M
$606.2M
Q2 25
$715.4M
$547.9M
Q1 25
$581.6M
$-84.6M
Q4 24
$822.6M
$316.9M
Q3 24
$706.5M
$438.4M
Q2 24
$620.5M
$489.1M
Free Cash Flow
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
$730.0M
$432.2M
Q3 25
$735.6M
$586.4M
Q2 25
$560.1M
$530.4M
Q1 25
$465.0M
$-108.0M
Q4 24
$510.6M
$309.9M
Q3 24
$458.6M
$410.0M
Q2 24
$311.1M
$462.4M
FCF Margin
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
25.5%
25.5%
Q3 25
29.4%
35.7%
Q2 25
23.0%
35.0%
Q1 25
20.6%
-7.1%
Q4 24
21.2%
19.5%
Q3 24
22.5%
27.1%
Q2 24
15.5%
31.2%
Capex Intensity
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
5.7%
1.4%
Q3 25
4.2%
1.2%
Q2 25
6.4%
1.2%
Q1 25
5.2%
1.5%
Q4 24
12.9%
0.4%
Q3 24
12.2%
1.9%
Q2 24
15.4%
1.8%
Cash Conversion
ISRG
ISRG
IVZ
IVZ
Q1 26
Q4 25
1.12×
Q3 25
1.19×
1.70×
Q2 25
1.09×
2.78×
Q1 25
0.83×
-0.49×
Q4 24
1.20×
1.51×
Q3 24
1.25×
7.97×
Q2 24
1.18×
3.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ISRG
ISRG

Instruments and accessories$1.7B61%
Systems$650.7M23%
Services$433.7M16%

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

Related Comparisons